PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Betahistine hydrochloride - Meniere's disease

PAD Profile : Betahistine hydrochloride - Meniere's disease

Keywords :
Meniere's syndrome, vertigo, hearing loss, tinnitus, vestibular disorders
Brand Names Include :
Serc

Traffic Light Status

Status 1 of 1.

Status :
Green
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
03 June 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey & North West Sussex Area Prescribing Committee (APC) recommend the prescribing o betahistine for the treatment of Meniere's Disease in line with NICE Clinical Knowledge Summaries (CKS) https://cks.nice.org.uk/menieres-disease  

NOTE - the branded product, Serc, was considered BLACK at the PCN in May 2017. https://surreyccg.res-systems.net/PAD/Search/DrugConditionProfile/5580

Associated BNF Codes

04. Central Nervous System
04.06.00. Drugs used in nausea and vertigo
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More